NYSE:ADCT
Adc Therapeutics Ltd Stock News
$3.43
-0.0100 (-0.291%)
At Close: May 31, 2024
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
07:15am, Thursday, 30'th May 2024
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Gl
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
07:15am, Wednesday, 15'th May 2024
LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wai
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
07:15am, Thursday, 09'th May 2024
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
11:04am, Monday, 06'th May 2024
ADC Therapeutics SA (NYSE:ADCT ) Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - CEO Kriste
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
08:21am, Monday, 06'th May 2024
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.74 per share a year ago.
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
07:30am, Monday, 06'th May 2024
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
06:10am, Monday, 06'th May 2024
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1Q 2023
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA ®
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Wednesday, 01'st May 2024
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 147,600 of the Company'
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patient
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
07:00am, Wednesday, 03'rd Apr 2024
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript
01:24pm, Wednesday, 13'th Mar 2024
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
09:21am, Wednesday, 13'th Mar 2024
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
07:00am, Wednesday, 13'th Mar 2024
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
07:15am, Wednesday, 06'th Mar 2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggen